R&D The founder of Eriochem discusses his firm’s ambitious technology based on a competitive IP strategy and its exciting research on a radically new oncology platform. Today, Eriochem is a vertically integrated company producing both APIs and final dosage forms; when you started the company, what was the strategy you followed…
oncology In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its go-to-market strategy and has succeeded in positioning itself as a top player in women’s health and primary care, lead by…
Oncology The following graph shows the comparitive spending on oncology products between 2010 and 2012 in the US, the EU, Japan, BRICs and other countries.
development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…
Internationalization José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and development in total, Zeltia was finally able to commercialize a novel product. Would you say that this investment was worth…
Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…
See our Cookie Privacy Policy Here